Viking Therapeutics, Inc.

VKTX · NasdaqCM

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders3.1%

Institutions66.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$393.34M	-$150.92M	-$70.36M	-$55.68M	-$42.66M	-$32.69M	-$26.16M	-$19.07M	-$13.85M	-$12.00M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$359.64M	-$109.96M	-$68.87M	-$54.99M	-$39.49M	-$25.78M	-$22.06M	-$20.58M	-$14.73M	-$23.40M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-3.19	$-1.01	$-0.90	$-0.71	$-0.54	$0.00	$0.00	$0.00	$0.00	$-3.00
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-3.19	$-1.01	$-0.90	–	–	–	–	–	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$165.81M	$26.68M	$36.63M	$26.37M	$29.12M	$8.38M	$24.78M	$8.99M	$3.08M	$768550
Everything the company owns that has value — cash, property, inventory, investments, and more.	$715.73M	$908.32M	$168.53M	$210.66M	$256.50M	$284.26M	$302.31M	$22.12M	$14.54M	$15.44M
All of the company's interest-bearing borrowings, short and long term combined.	–	–	–	–	–	–	–	$3.45M	$3.27M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$76.67M	$28.04M	$23.21M	$8.78M	$12.16M	$7.14M	$4.56M	$8.66M	$6.49M	$6.71M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$639.06M	$880.28M	$145.32M	$201.88M	$244.34M	$277.12M	$297.75M	$13.46M	$8.04M	$8.72M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$278.69M	-$87.79M	-$48.40M	-$47.59M	-$21.78M	-$24.75M	-$18.75M	-$14.76M	-$11.07M	-$8.73M

	You	Peer avg
Revenue Growth	–	+23.1%
ROE	-88.9%	-25.4%

Viking Therapeutics, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison